This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palmieri, G. Articles by Castello, G. Search for Related Content PubMed PubMed Citation Articles by Palmieri, G. Articles by Castello, G. Social Bookmarking                            What's this?

Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression

From the Divisions of Clinical Immunology and Medical Oncology A, Department of Medicine, National Tumor Institute, Naples, Italy.

Address reprint requests to Dr. Giuseppe Castello, Division of Clinical Immunology, National Tumor Institute "G. Pascale," Via M. Semmola, 80131 Naples, Italy

PURPOSE: Reverse transcriptase (RT) polymerase chain reaction (PCR) with multiple markers has been demonstrated to be highly sensitive in detecting circulating cells from patients with malignant melanoma (MM). We evaluated the clinical significance of the presence in peripheral blood of specific PCR-positive mRNA markers as an expression of circulating melanoma cells.

PATIENTS AND METHODS: Total cellular RNA was obtained from the peripheral blood of 235 patients with either localized (n = 154) or metastatic (n = 81) melanoma. We performed RT-PCR using tyrosinase, p97, MUC18, and MelanA/MART1 as gene markers. The PCR products were analyzed by gel electrophoresis and Southern blot hybridization. In addition, 20 healthy subjects and 21 patients with nonmelanoma cancer were used as negative controls.

RESULTS: Although detected at various levels among assessable patients, each mRNA marker was significantly correlated with disease stage. A significant correlation with disease stage was demonstrated for patients who were positive to all four markers (P < .0001) or to at least three markers (P < .001). Univariate analysis showed a significant correlation between risk of recurrence (evaluated in stage I, II, and III patients) and increasing number of PCR-positive markers (P = .0002). Logistic regression multivariate analysis indicated that each single marker (except tyrosinase) and, more especially, the presence of four PCR-positive markers remained statistically independent prognostic factors for tumor progression.

CONCLUSION: Our data establish the existence of a significant correlation among clinical stages, tumor progression, and presence of circulating melanoma-associated antigens in peripheral blood of MM patients. Preliminary assessment of a subset of patients with a higher risk of recurrence needs longer follow-up and further studies to define the role of RT-PCR in monitoring MM patients.

Drs. Palmieri and Strazzulo contributed equally to this work.

Present address of Dr. Palmieri is Institute of Molecular Genetics, Alghero (SS), Italy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Kitago, K. Koyanagi, T. Nakamura, Y. Goto, M. Faries, S. J. O'Day, D. L. Morton, S. Ferrone, and D. S.B. Hoon mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads Clin. Chem., April 1, 2009; 55(4): 757 - 764. [Abstract] [Full Text] [PDF]

				R. Schuster, N. E. Bechrakis, A. Stroux, A. Busse, A. Schmittel, C. Scheibenbogen, E. Thiel, M. H. Foerster, and U. Keilholz Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma Clin. Cancer Res., February 15, 2007; 13(4): 1171 - 1178. [Abstract] [Full Text] [PDF]

				X.-S. Wang, Z. Zhang, H.-C. Wang, J.-L. Cai, Q.-W. Xu, M.-Q. Li, Y.-C. Chen, X.-P. Qian, T.-J. Lu, L.-Z. Yu, et al. Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma. Clin. Cancer Res., August 15, 2006; 12(16): 4851 - 4858. [Abstract] [Full Text] [PDF]

				K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res., June 15, 2006; 66(12): 6111 - 6117. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al. Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064. [Abstract] [Full Text] [PDF]

				T. G. Zogakis, R. Essner, H.-j. Wang, R. R. Turner, Y. T. Takasumi, R. L. Gaffney, J. H. Lee, and D. L. Morton Melanoma Recurrence Patterns After Negative Sentinel Lymphadenectomy Arch Surg, September 1, 2005; 140(9): 865 - 872. [Abstract] [Full Text] [PDF]

				C. Voit, M. Kron, J. Rademaker, M. Schwurzer-Voit, W. Sterry, L. Weber, C. Ozdemir, T. Proebstle, and U. Keilholz Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival J. Clin. Oncol., February 20, 2005; 23(6): 1218 - 1227. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]

				H. Takeuchi, D. L. Morton, C. Kuo, R. R. Turner, D. Elashoff, R. Elashoff, B. Taback, A. Fujimoto, and D. S.B. Hoon Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients J. Clin. Oncol., July 1, 2004; 22(13): 2671 - 2680. [Abstract] [Full Text] [PDF]

				U. Keilholz, P. Goldin-Lang, N. E. Bechrakis, N. Max, A. Letsch, A. Schmittel, C. Scheibenbogen, K. Heufelder, A. Eggermont, and E. Thiel Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Clin. Cancer Res., March 1, 2004; 10(5): 1605 - 1612. [Abstract] [Full Text] [PDF]

				J. Szenajch, B. Jasinski, A. Synowiec, J. Kulik, M. Chomicka, J. Struzyna, Z. Nowecki, P. Rutkowski, W. Ruka, W. Kupsc, et al. Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma Clin. Chem., September 1, 2003; 49(9): 1450 - 1457. [Abstract] [Full Text] [PDF]

				R. A. Wascher, D. L. Morton, C. Kuo, R. M. Elashoff, H.-J. Wang, M. Gerami, and D. S.B. Hoon Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine J. Clin. Oncol., July 1, 2003; 21(13): 2558 - 2563. [Abstract] [Full Text] [PDF]

				S. R. Reynolds, J. Albrecht, R. L. Shapiro, D. F. Roses, M. N. Harris, A. Conrad, A. Zeleniuch-Jacquotte, and J.-C. Bystryn Changes in the Presence of Multiple Markers of Circulating Melanoma Cells Correlate with Clinical Outcome in Patients with Melanoma Clin. Cancer Res., April 1, 2003; 9(4): 1497 - 1502. [Abstract] [Full Text] [PDF]

				J. P. Dutcher The Prognostic Role of Detection of Circulating Melanoma Cells in the Blood J. Clin. Oncol., March 1, 2003; 21(5): 757 - 759. [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, F. Perrone, S. M.R. Satriano, A. Ottaiano, A. Daponte, M. Napolitano, C. Caraco, N. Mozzillo, M. T. Melucci, et al. Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction J. Clin. Oncol., March 1, 2003; 21(5): 767 - 773. [Abstract] [Full Text] [PDF]

				B. Mellado, M. del Carmen Vela, D. Colomer, L. Gutierrez, T. Castel, L. Quinto, M. Fontanillas, N. Reguart, J. M. Domingo-Domenech, C. Montagut, et al. Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon J. Clin. Oncol., October 1, 2002; 20(19): 4032 - 4039. [Abstract] [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, A. Cossu, N. Mozzillo, M. L. Motti, S. M.R. Satriano, G. Botti, C. Caraco, E. Celentano, R. A. Satriano, et al. Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay J. Clin. Oncol., March 1, 2001; 19(5): 1437 - 1443. [Abstract] [Full Text] [PDF]

				H. Tsao, U. Nadiminti, A. J. Sober, and M. Bigby A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma Arch Dermatol, March 1, 2001; 137(3): 325 - 330. [Abstract] [Full Text] [PDF]

				B. S. Sorensen, H. Schmidt, H. von der Maase, P. T. Straten, and E. Nexo Quantification of Melanoma Cell-specific MART-1 mRNA in Peripheral Blood by a Calibrated Competitive Reverse Transcription-PCR Clin. Chem., December 1, 2000; 46(12): 1923 - 1928. [Abstract] [Full Text] [PDF]

				D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence Cancer Res., April 1, 2000; 60(8): 2253 - 2257. [Abstract] [Full Text]